DE69931640D1 - Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen - Google Patents

Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen

Info

Publication number
DE69931640D1
DE69931640D1 DE69931640T DE69931640T DE69931640D1 DE 69931640 D1 DE69931640 D1 DE 69931640D1 DE 69931640 T DE69931640 T DE 69931640T DE 69931640 T DE69931640 T DE 69931640T DE 69931640 D1 DE69931640 D1 DE 69931640D1
Authority
DE
Germany
Prior art keywords
treatment
acetylcholinesterasis
medicament
inhibitors
functional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69931640T
Other languages
English (en)
Other versions
DE69931640T2 (de
Inventor
Maria Nicolodi
Federigo Sicuteri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of DE69931640D1 publication Critical patent/DE69931640D1/de
Application granted granted Critical
Publication of DE69931640T2 publication Critical patent/DE69931640T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69931640T 1998-09-11 1999-09-09 Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen Expired - Lifetime DE69931640T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1998FI000208A IT1304904B1 (it) 1998-09-11 1998-09-11 Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
ITFI980208 1998-09-11
PCT/EP1999/006648 WO2000015205A2 (en) 1998-09-11 1999-09-09 Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes

Publications (2)

Publication Number Publication Date
DE69931640D1 true DE69931640D1 (de) 2006-07-06
DE69931640T2 DE69931640T2 (de) 2007-03-08

Family

ID=11352669

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69931640T Expired - Lifetime DE69931640T2 (de) 1998-09-11 1999-09-09 Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen

Country Status (12)

Country Link
US (1) US6608088B1 (de)
EP (1) EP1112067B1 (de)
JP (1) JP3984787B2 (de)
AT (1) ATE327740T1 (de)
AU (1) AU5861799A (de)
CY (1) CY1105125T1 (de)
DE (1) DE69931640T2 (de)
DK (1) DK1112067T3 (de)
ES (1) ES2265691T3 (de)
IT (1) IT1304904B1 (de)
PT (1) PT1112067E (de)
WO (1) WO2000015205A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1311272E (pt) 2000-03-03 2007-02-28 Eisai R&D Man Co Ltd Novos métodos utilizando inibidores de colinesterase
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
BR0110188A (pt) * 2000-04-21 2003-03-05 Upjohn Co Compostos selecionados para o tratamento de sìndromes de fibromialgia e de fadiga crÈnica
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
NZ556761A (en) * 2005-01-25 2011-04-29 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
WO2006086698A2 (en) * 2005-02-11 2006-08-17 Stephen Wills Treating microvasculature diseases with acetyl cholinesterase inhibitors
AU2006232517A1 (en) * 2005-04-04 2006-10-12 Eisai R&D Management Co., Ltd. Dihydropyridine compounds and compositions for headaches
JP2009541368A (ja) * 2006-07-05 2009-11-26 天津和美生物技▲術▼有限公司 鎮痛性５，９−メタノシクロオクタ（ｂ）ピリジン−２−（１Ｈ）−オン誘導体、その作成方法と用途
US8012994B1 (en) 2006-09-22 2011-09-06 Sevastyanov Victor V Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®)
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2865670B1 (de) 2007-04-18 2017-01-11 Probiodrug AG Thioharnstoffderivative als Glutaminylcyclaseinhibitoren
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
EP2475428B1 (de) 2009-09-11 2015-07-01 Probiodrug AG Heterocyclische derivate als glutaminylcyclase-hemmer
JP6082250B2 (ja) 2010-02-09 2017-02-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 認知機能を改善するための方法および組成物
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP2015078129A (ja) * 2012-02-01 2015-04-23 株式会社新日本科学 ドネペジルを含む線維筋痛症の治療剤
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (de) 2013-03-15 2021-05-05 Agenebio, Inc. Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010083A (en) 1988-03-28 1991-04-23 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-methano-1,3-benzodiazocine compounds which have useful pharmaceutical utility
DE3927049A1 (de) 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
US5336675A (en) 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
WO1999008672A1 (en) 1997-08-15 1999-02-25 Shire International Licensing Bv Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity

Also Published As

Publication number Publication date
JP3984787B2 (ja) 2007-10-03
IT1304904B1 (it) 2001-04-05
WO2000015205A3 (en) 2000-08-24
ES2265691T3 (es) 2007-02-16
CY1105125T1 (el) 2009-11-04
ATE327740T1 (de) 2006-06-15
WO2000015205A2 (en) 2000-03-23
JP2002524498A (ja) 2002-08-06
EP1112067A2 (de) 2001-07-04
DK1112067T3 (da) 2006-09-04
ITFI980208A1 (it) 2000-03-11
PT1112067E (pt) 2006-09-29
ITFI980208A0 (it) 1998-09-11
AU5861799A (en) 2000-04-03
US6608088B1 (en) 2003-08-19
EP1112067B1 (de) 2006-05-31
DE69931640T2 (de) 2007-03-08

Similar Documents

Publication Publication Date Title
DE69931640D1 (de) Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DK0751789T3 (da) Gel til behandling af hudsygdomme og til desinfektion af huden
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DK0801564T3 (da) Anvendelse af nebivolol som et antiatherogent middel
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
DE69526937T2 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE60139466D1 (de) Behandlung von diabetes
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
HUP0000873A2 (hu) A levobupivakain arcsebészeti alkalmazása
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60100660D1 (de) Verwendung von modafinil zur herstellung eines arzneimittels zur behandlung von vigilanzstörungen im zusammenhang mit myopathien
HUP0001913A2 (hu) Pramipexole alkalmazása állandóan mozgó láb szindróma kezelésére szolgáló gyógyszerkészítmények előállítására
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
ATE275949T1 (de) Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BONGEN, RENAUD & PARTNER, 70173 STUTTGART

8327 Change in the person/name/address of the patent owner

Owner name: EISAI R&D MANAGEMENT CO., LTD., TOKYO, JP